632 NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naïve MSS/MSI-L colorectal cancer (CRC)
Barbu A, Kothari P, Kahan S, Christenson E, Kazmi S, Manda S, Chisamore M, Kordahi S, Martz A, Nelson M, Morawski A, Flies D, Langermann S, Guha U, Myint H. 632 NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naïve MSS/MSI-L colorectal cancer (CRC). 2024, a727-a727. DOI: 10.1136/jitc-2024-sitc2024.0632.Peer-Reviewed Original Research